Essential information for neurorecovery clinical trial design: trajectory of global disability in first 90 days post-stroke in patients discharged to acute rehabilitation facilities.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
20 Jun 2023
Historique:
received: 25 11 2022
accepted: 18 05 2023
medline: 22 6 2023
pubmed: 21 6 2023
entrez: 20 6 2023
Statut: epublish

Résumé

Many stroke recovery interventions are most beneficial when started 2-14d post-stroke, a time when patients become eligible for inpatient rehabilitation facilities (IRF) and neuroplasticity is often at its peak. Clinical trials focused on recovery need to expand the time from this plasticity to later outcome timepoints. The disability course of patients with acute ischemic stroke (AIS) and intracranial hemorrhage (ICH) enrolled in Field Administration of Stroke Therapy Magnesium (FAST-MAG) Trial with moderate-severe disability (modified Rankin Scale [mRS] 3-5) on post-stroke day4 who were discharged to IRF 2-14d post-stroke were analyzed. Among 1422 patients, 446 (31.4%) were discharged to IRFs, including 23.6% within 2-14d and 7.8% beyond 14d. Patients with mRS 3-5 on day4 discharged to IRFs between 2-14d accounted for 21.7% (226/1041) of AIS patients and 28.9% (110/381) of ICH patients, (p < 0.001). Among these AIS patients, age was 69.8 (± 12.7), initial NIHSS median 8 (IQR 4-12), and day4 mRS = 3 in 16.4%, mRS = 4 in 50.0%, and mRS = 5 in 33.6%. Among these ICH patients, age was 62.4 (± 11.7), initial NIHSS median 9 (IQR 5-13), day 4 mRS = 3 in 9.4%, mRS = 4 in 45.3%, and mRS = 5 in 45.3% (p < 0.01 for AIS vs ICH). Between day4 to day90, mRS improved ≥ 1 levels in 72.6% of AIS patients vs 77.3% of ICH patients, p = 0.3. For AIS, mRS improved from mean 4.17 (± 0.7) to 2.84 (± 1.5); for ICH, mRS improved from mean 4.35 (± 0.7) to 2.75 (± 1.3). Patients discharged to IRF beyond day14 had less improvement on day90 mRS compared with patients discharged between 2-14d. In this acute stroke cohort, nearly 1 in 4 patients with moderate-severe disability on post-stroke day4 were transferred to IRF within 2-14d post-stroke. ICH patients had nominally greater mean improvement on mRS day90 than AIS patients. This course delineation provides a roadmap for future rehabilitation intervention studies.

Sections du résumé

BACKGROUND BACKGROUND
Many stroke recovery interventions are most beneficial when started 2-14d post-stroke, a time when patients become eligible for inpatient rehabilitation facilities (IRF) and neuroplasticity is often at its peak. Clinical trials focused on recovery need to expand the time from this plasticity to later outcome timepoints.
METHODS METHODS
The disability course of patients with acute ischemic stroke (AIS) and intracranial hemorrhage (ICH) enrolled in Field Administration of Stroke Therapy Magnesium (FAST-MAG) Trial with moderate-severe disability (modified Rankin Scale [mRS] 3-5) on post-stroke day4 who were discharged to IRF 2-14d post-stroke were analyzed.
RESULTS RESULTS
Among 1422 patients, 446 (31.4%) were discharged to IRFs, including 23.6% within 2-14d and 7.8% beyond 14d. Patients with mRS 3-5 on day4 discharged to IRFs between 2-14d accounted for 21.7% (226/1041) of AIS patients and 28.9% (110/381) of ICH patients, (p < 0.001). Among these AIS patients, age was 69.8 (± 12.7), initial NIHSS median 8 (IQR 4-12), and day4 mRS = 3 in 16.4%, mRS = 4 in 50.0%, and mRS = 5 in 33.6%. Among these ICH patients, age was 62.4 (± 11.7), initial NIHSS median 9 (IQR 5-13), day 4 mRS = 3 in 9.4%, mRS = 4 in 45.3%, and mRS = 5 in 45.3% (p < 0.01 for AIS vs ICH). Between day4 to day90, mRS improved ≥ 1 levels in 72.6% of AIS patients vs 77.3% of ICH patients, p = 0.3. For AIS, mRS improved from mean 4.17 (± 0.7) to 2.84 (± 1.5); for ICH, mRS improved from mean 4.35 (± 0.7) to 2.75 (± 1.3). Patients discharged to IRF beyond day14 had less improvement on day90 mRS compared with patients discharged between 2-14d.
CONCLUSIONS CONCLUSIONS
In this acute stroke cohort, nearly 1 in 4 patients with moderate-severe disability on post-stroke day4 were transferred to IRF within 2-14d post-stroke. ICH patients had nominally greater mean improvement on mRS day90 than AIS patients. This course delineation provides a roadmap for future rehabilitation intervention studies.

Identifiants

pubmed: 37340330
doi: 10.1186/s12883-023-03251-1
pii: 10.1186/s12883-023-03251-1
pmc: PMC10280859
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

239

Informations de copyright

© 2023. The Author(s).

Références

Lancet. 2011 May 14;377(9778):1693-702
pubmed: 21571152
Stroke. 2007 Apr;38(4):1393-5
pubmed: 17332455
Lancet Neurol. 2017 May;16(5):360-368
pubmed: 28320635
J Pers Med. 2021 Nov 02;11(11):
pubmed: 34834489
S Afr Med J. 2012 May 23;102(6):545-8
pubmed: 22668960
Arch Phys Med Rehabil. 2003 Jul;84(7):968-72
pubmed: 12881818
Neuropsychiatr Dis Treat. 2020 Aug 13;16:1975-1985
pubmed: 32884273
Neurorehabil Neural Repair. 2015 Sep;29(8):743-54
pubmed: 25567120
Neurorehabil Neural Repair. 2021 Apr;35(4):307-320
pubmed: 33576318
Diagnostics (Basel). 2020 Dec 28;11(1):
pubmed: 33379391
Transl Stroke Res. 2017 Feb;8(1):33-46
pubmed: 27109642
Stroke. 2016 Jun;47(6):e98-e169
pubmed: 27145936
J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105332
pubmed: 32992179
Stroke. 2021 Mar;52(3):1154-1161
pubmed: 33563009
Neurosurg Focus. 2016 May;40(5):E2
pubmed: 27132523
Disabil Rehabil. 2015;37(15):1316-23
pubmed: 25250807
Neurorehabil Neural Repair. 2012 Oct;26(8):923-31
pubmed: 22466792
Stroke. 2021 Oct;52(10):3082-3087
pubmed: 34465201
J Neurophysiol. 2019 Jul 1;122(1):350-357
pubmed: 31141442
Lancet Neurol. 2020 Apr;19(4):348-360
pubmed: 32004440
N Engl J Med. 2015 Feb 5;372(6):528-36
pubmed: 25651247
Semin Neurol. 2018 Apr;38(2):208-211
pubmed: 29791947
PM R. 2009 May;1(5):427-33
pubmed: 19627929
Arch Phys Med Rehabil. 2017 Apr;98(4):759-765
pubmed: 27993584
PLoS One. 2014 Feb 04;9(2):e87987
pubmed: 24505342
Stroke. 2003 Dec;34(12):2861-5
pubmed: 14615613
Arch Phys Med Rehabil. 2021 Aug;102(8):1473-1481
pubmed: 33684363
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852

Auteurs

Shayandokht Taleb (S)

Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA. talebshayandokht@gmail.com.
Department of Neurology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, USA. talebshayandokht@gmail.com.

Jenny Ji-Hyun Lee (JJ)

Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.

Pamela Duncan (P)

Department of Neurology, Wake Forest School of Medicine, Winston-Salem, USA.

Steven C Cramer (SC)

Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.

Mersedeh Bahr-Hosseini (M)

Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.

Michael Su (M)

Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.

Sidney Starkman (S)

Departments of Emergency Medicine and Neurology, David Geffen School of Medicine at UCLA, Los Angeles, USA.

Gilda Avila (G)

Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.

Arielle Hochberg (A)

BrainQ Technologies Ltd, Jerusalem, Israel.

Scott Hamilton (S)

Department of Neurology, Stanford University, Stanford, USA.

Robin A Conwit (RA)

National Institute of Neurological Disorders and Stroke, Bethesda, USA.

Jeffrey L Saver (JL)

Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH